Tacere Secures Financing and Resumes Development of RNAi Hepatitis C Drug

Tacere Therapeutics, Inc. has announced that the company has secured an undisclosed amount of seed financing from Hokkaido Venture Capital, and has thus established operations and resumed preclinical development of TT-033i, its lead candidate for the treatment of Hepatitis C (HCV).

Sara Cunningham Hall, President and Chief Executive Officer of Tacere, stated, "As pioneers in RNA interference we are pleased to resume development of TT-033i, a drug that we have taken from concept to preclinical studies over the last several years."

"Initiated at Avocel, Inc. and furthered at Benitec Ltd., our expertise in Hepatitis C and RNAi allows Tacere to begin corporate life with a great deal of experience and a competitively staged clinical program."

"The company will also capitalize on its extensive knowledge of HCV to advance a number of novel small molecule compounds for the treatment of this viral disease."

"Broader market acceptance and lower regulatory hurdles continue to drive the development of small molecule antivirals."

"However, the emergence of RNAi as a legitimate therapeutic modality offers a powerful new approach to treating HCV. We look forward to returning to the forefront of this exciting technology."

Mike Catelani, Chairman, Senior Vice President, and Chief Financial Officer of Tacere, remarked, "It's not often that one has the opportunity to take the best of a technology and implement it anew in a sound and well-supported corporate structure."

"Tacere recently exclusively in-licensed from Benitec Ltd. the RNAi drug development program that this team has been advancing toward the clinic over the past four years."

"Tacere staff and management, with the support of a strong group of directors and scientific advisors, are well-positioned to move this program forward and meet the challenges of developing both traditional and novel therapeutics."